Protease‐activated receptor‐2 accelerates intestinal tumor formation through activation of nuclear factor‐κB signaling and tumor angiogenesis in Apc Min/+ mice

Makiko Kawaguchi,Koji Yamamoto,Hiroaki Kataoka,Aya Izumi,Fumiki Yamashita,Takumi Kiwaki,Takahiro Nishida,Eric Camerer,Tsuyoshi Fukushima
DOI: https://doi.org/10.1111/cas.14335
IF: 5.7
2020-02-24
Cancer Science
Abstract:<p>Hepatocyte growth factor activator inhibitor‐1 (HAI‐1), encoded by the <i>SPINT1</i> gene, is a membrane‐bound protease inhibitor expressed on the surface of epithelial cells. HAI‐1 regulates type II transmembrane serine proteases that activate protease‐activated receptor‐2 (PAR‐2). We previously reported that deletion of <i>Spint1</i> in <i>Apc</i><sup>Min/+</sup> mice resulted in accelerated formation of intestinal tumors, possibly through enhanced NF‐κB signaling. In this study, we examined the role of PAR‐2 in accelerating tumor formation in the <i>Apc</i><sup>Min/+</sup> model in the presence or absence of <i>Spint1</i>. We observed that knockout of the <i>F2rl1</i> gene, encoding PAR‐2, not only eliminated the enhanced formation of intestinal tumors caused by <i>Spint1</i> deletion, but also reduced tumor formation in the presence of <i>Spint1</i>. Exacerbation of anemia and weight loss associated with HAI‐1 deficiency was also normalized by compound deficiency of PAR‐2. Mechanistically, signaling triggered by deregulated protease activities increased nuclear translocation of RelA/p65, vascular endothelial growth factor expression, and vascular density in <i>Apc</i><sup>Min/+</sup> ‐induced intestinal tumors. These results suggest that serine proteases promote intestinal carcinogenesis through activation of PAR‐2, and that HAI‐1 plays a critical tumor suppressor role as an inhibitor of matriptase, kallikreins, and other PAR‐2 activating proteases.</p>
oncology
What problem does this paper attempt to address?